TNFRSF8 and lymphoma: ADCs useful in pediatric cancers include Inotuzumab, Gemtuzumab (humanised anti-CD33-calicheamicin conjugate), Brentuximab [anti-CD30 monoclonal antibody-monomethyl auristatin E conjugate] for leukemia/lymphoma [19, 21].